Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/what-is-a-new-drug-worth-an-innovative-model-for-performance-based-mrW4j2DfCr
References (21)
-
Camille Abboud, Ellin Berman, Adam Cohen, J. Cortes, D. DeAngelo, M. Deininger, Steven Devine, B. Druker, Amir Fathi, E. Jabbour, M. Jagasia, H. Kantarjian, Jean Khoury, Pierre Laneuville, Richard Larson, J. Lipton, Joseph Moore, T. Mughal, Susan O’Brien, J. Pinilla-Ibarz, A. Quintás-Cardama, J. Radich, Vishnu Reddy, Charles Schiffer, Neil Shah, P. Shami, Richard Silver, David Snyder, Richard Stone, M. Talpaz, A. Tefferi, R. Etten, M. Wetzler, E. Abruzzese, J. Apperley, M. Breccia, Jenny Byrne, Francisco Cervantes, E. Chelysheva, Richard Clark, H. Lavallade, Iryna Dyagil, C. Gambacorti-Passerini, J. Goldman, İ. Haznedaroğlu, H. Hjorth-Hansen, T. Holyoake, B. Huntly, P. Coutre, E. Lomaia, F. Mahon, David Marin-Costa, Giovanni Martinelli, Jiří Mayer, D. Milojkovic, Eduardo Olavarria, K. Porkka, Johan Richter, Philippe Rousselot, G. Saglio, G. Saydam, J. Stentoft, A. Turkina, Paolo Vigneri, A. Zaritskey, Alvaro Aguayo, M. Ayala, Israel Bendit, R. Bengió, Carlos Best, Eduardo Bullorsky, E. Cervera, Carmino DeSouza, E. Fanilla, D. Gómez-Almaguer, N. Hamerschlak, Jose Lopez, A. Magariños, L. Meillon, J. Milone, B. Moiraghi, R. Pasquini, C. Pavlovsky, G. Ruiz-Argüelles, Nelson Spector, Christopher Arthur, P. Browett, Andrew Grigg, Jianda Hu, Xiao-jun Huang, T. Hughes, Qian Jiang, S. Jootar, Dong-Wook Kim, Hemant Malhotra, Pankaj Malhotra, I. Matsumura, Junia Melo, K. Ohnishi, Ryuzo Ohno, Tapan Saikia, A. Schwarer, N. Takahashi, Constantine Tam, Tetsuzo Tauchi, K. Usuki, Jianxiang Wang, Fawzi Abdel-Rahman, M. Aljurf, A. Bazarbachi, D. Yehuda, N. Chaudhri, M. Durosinmi, Hossam Kamel, Vernon Louw, B. Matti, A. Nagler, Pia Raanani, Ziad Salem (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.Blood, 121 22
-
E. Kolassa (2009)
The Strategic Pricing of Pharmaceuticals -
J. Guo, Y. Jing, K. Nguyen, H. Fan, Xing Li, C. Kelton (2008)
Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmesJournal of Medical Economics, 11
-
B. O'brien, A. Gafni (1996)
When Do the "Dollars" Make Sense?Medical Decision Making, 16
-
Towse Towse, Garrison Garrison (2010)
Can't get no satisfaction? Will pay for performance help?: Toward an economic framework for understanding performance‐based risk‐sharing agreements for innovative medical productsPharmacoeconomics, 28
-
O'Brien O'Brien, Gafni Gafni (1996)
When do the ‘Dollars’ make sense? Toward a conceptual framework for contingent valuation studies in health careMedical Decision Making: An International Journal of the Society for Medical Decision Making, 16
-
M. Bala, G. Zarkin (2000)
Are QALYs an appropriate measure for valuing morbidity in acute diseases?Health economics, 9 2
-
A. Towse, L. Garrison (2012)
Can’t Get No Satisfaction? Will Pay for Performance Help?PharmacoEconomics, 28
-
F. Scherer (2004)
The pharmaceutical industry--prices and progress.The New England journal of medicine, 351 9
-
Peter Orszag, Philip Ellis (2007)
The challenge of rising health care costs--a view from the Congressional Budget Office.The New England journal of medicine, 357 18
-
J. Hoffman, E. Li, F. Doloresco, Linda Matusiak, R. Hunkler, N. Shah, L. Vermeulen, G. Schumock (2012)
Projecting future drug expenditures--2012.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 69 5
-
J. Raftery (2013)
Value based pricing: can it work?BMJ : British Medical Journal, 347
-
B. Hillner, Thomas Smith (2009)
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 13
-
M. Drummond, A. Mason (2007)
European perspective on the costs and cost-effectiveness of cancer therapies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 2
-
Anonymous Anonymous (2013)
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsBlood, 121
-
P. Cremieux, P. Ouellette, P. Petit (2012)
Do Drugs Reduce Utilisation of Other Healthcare Resources?PharmacoEconomics, 25
-
Pouvourville Pouvourville (2006)
Risk‐sharing agreements for innovative drugs: a new solution to old problems?The European Journal of Health Economics, 7
-
C. Jackevicius, J. Cox, Daniel Carreon, J. Tu, S. Rinfret, D. So, H. Johansen, D. Kalavrouziotis, V. Demers, K. Humphries, L. Pilote (2009)
Long-term trends in use of and expenditures for cardiovascular medications in CanadaCanadian Medical Association Journal, 181
-
Bengt Jönsson, N. Wilking (2007)
A global comparison regarding patient access to cancer drugs.Annals of oncology : official journal of the European Society for Medical Oncology, 18 Suppl 3
-
G. Pouvourville (2006)
Risk-sharing agreements for innovative drugsThe European Journal of Health Economics, 7
-
T. Fojo, C. Grady (2009)
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.Journal of the National Cancer Institute, 101 15
- Publisher
- Wiley
- Copyright
- Copyright © 2015 John Wiley & Sons Ltd
- ISSN
- 0961-5423
- eISSN
- 1365-2354
- DOI
- 10.1111/ecc.12240
- pmid
- 25256668
- Publisher site
- See Article on Publisher Site
Abstract
This article focuses on a novel method to derive prices for new pharmaceuticals by making price a function of drug performance. We briefly review current models for determining price for a new product and discuss alternatives that have historically been favoured by various funding bodies. The progressive approach to drug pricing, proposed herein, may better address the views and concerns of multiple stakeholders in a developed healthcare system by acknowledging and incorporating input from disparate parties via comprehensive and successive negotiation stages. In proposing a valid construct for performance‐based pricing, the following model seeks to achieve several crucial objectives: earlier and wider access to new treatments; improved transparency in drug pricing; multi‐stakeholder involvement through phased pricing negotiations; recognition of innovative product performance and latent changes in value; an earlier and more predictable return for developers without sacrificing total return on investment (ROI); more involved and informed risk sharing by the end‐user.
Journal
European Journal of Cancer Care – Wiley
Published: May 1, 2015